logo-loader
Hays PLC

Hays weak as Morgan Stanley cuts its rating to ‘equal-weight’ from ‘overweight’ on lack of near-term catalysts

Morgan Stanley’s analysts noted that with its half-year results in February, Hays flagged a lower level of contractor extensions in its biggest market, Germany

Hays sign
The US investment bank also chopped its target price for the FTSE 250-listed firm down to 185p from 200p

Morgan Stanley gave a knock to Hays PLC (LON:HAS) on Tuesday, downgrading its rating for the staffing group to ‘equal-weight’ from ‘overweight’ ahead of a third-quarter trading update next week, pointing to a lack of near-term catalysts.

The US investment bank also chopped its target price for the FTSE 250-listed firm down to 185p from 200p, with the shares currently trading at 149.90p, off 1.8% from Monday’s close.

READ: Hays shares hit by fears of German slowdown despite first-half profit growth

In a note to clients, Morgan Stanley’s analysts noted that with its half-year results in February, Hays flagged a lower level of contractor extensions in its biggest market Germany, which will modestly reduce their overall growth rate.

They pointed out that, in their view, with slowing growth in Germany and in Australia – which together account for around 65% of the company’s operating profit – the stock will struggle to outperform near-term.

The analysts said they would need to see an inflection in growth momentum or higher visibility in at least one of those markets before taking a more positive view on the business again.

Quick facts: Hays PLC

Price: £1.53

Market: LSE
Market Cap: £2.23 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan 'driving research for novel drug development for rare diseases'

Proactive London sits down with Open Orphan PLC's (LON:ORPH) chief operating officer Maurice Treacy. Treacy discusses how he became involved with Open Orphan and his ambitions for the firm's health data initiative. ''Many rare diseases aren't known or badly diagnosed ... but rare isn't...

31 minutes ago

RNS

Director/PDMR Shareholding

4 days, 3 hours ago

Director/PDMR Shareholding

1 week, 3 days ago

Block Listing Application

1 week, 4 days ago

Total Voting Rights

2 weeks ago

Director/PDMR Shareholding

2 weeks, 3 days ago

Final Results

2 weeks, 4 days ago

2 min read